Boston Scientific (BSX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Boston Scientific Corporation (NYSE:BSX ) TD Cowen 45th Annual Healthcare Conference March 4, 2025 9:10 AM ET Company Participants Dan Brennan - Chief Financial Officer Ken Stein - Chief Medical Officer Art Butcher - Executive Vice President, MedSurg and APAC Conference Call Participants Josh Jennings - TD Cowen Josh Jennings Good morning. I'm Josh Jennings from the TD Cowen Medical Devices research team, and joined by Brian Kennedy and Eric Anderson, and we're excited to kick off Day 2 of the 45th Annual TD Cowen Healthcare Conference and thrilled to have executives from the Boston Scientific management team joining us and spending time with us this week.
Boston Scientific inks a deal to acquire the remaining 90% stake in SoniVie Ltd.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here is how Boston Scientific (BSX) and Abivax SA Sponsored ADR (ABVX) have performed compared to their sector so far this year.
Boston Scientific begins 2025 on a solid note, expecting organic revenue growth of 14% to 16% in the first quarter.
Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States.
Boston Scientific stock (NYSE: BSX) has gained 3% in the five days since its Q4 earnings report last week. Although the company exceeded expectations with both its results and guidance, the modest stock increase may be due to the significant price appreciation ahead of the earnings announcement.
BSX, ENVA and CFR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 10, 2025.
PFIS, BSX, ENVA, NFG and NLY have been added to the Zacks Rank #1 (Strong Buy) List on February 10, 2025.
Does Boston Scientific (BSX) have what it takes to be a top stock pick for momentum investors? Let's find out.